Low Coverage, Vaccine Hesitancy: Far Way to Go after HPV Vaccine Launched in Mainland China - Evidence from a Greater Bay Area Survey

中国 推出 中国大陆 海湾 大陆 医学 地理 工程类 考古 电气工程
作者
Yu Ma,Cuixiu Wang,Fanghua Liu,Guixiong Lian,Shuxue Li,Qing He,Tiegang Li
出处
期刊:Social Science Research Network [RELX Group (Netherlands)]
被引量:1
标识
DOI:10.2139/ssrn.3371078
摘要

Background: Human papillomavirus (HPV) vaccine was proved as one of the effective strategies in disease prevention and have been implemented successfully in most high-income countries. In 2018, WHO called for elimination action of cervical cancer as a public health problem and global action to scale-up vaccination. However, morbidity and mortality of cervical cancer in China showed in a rising trend in the past 3 decades. Bivalent, quadrivalent and nine-valent HPV vaccines were launched in China respectively until from July 2017 to the end of 2018, but lack of national coverage information. As the biggest developing country with largest population in low-income and middle-income countries (LMICs), HPV vaccination status and female's willing will be the nonnegligible factors considered in a global cervical cancer elimination strategy at the World Health Assembly to be held in May, 2020. In this survey, we aimed to assess the vaccination rate for all these three HPV vaccines and HPV screening rate in college students from Guangdong-Hong Kong-Macao Greater Bay Area (GBA) in China, to evaluate the influence factors for their vaccination and also reasons for their attitude. Methods: HPV vaccine vaccination records after HPV vaccine marked in China were collected from Guangzhou (biggest city in GBA) vaccination system. From October to December, 2018, we conducted a face to face questionnaire with students from 12 colleges in GBA university town. HPV vaccine vaccination and HPV screening behavior were self-reported by interviewee and vaccination was double checked in vaccination system via ID card number. Knowledge level and attitude were estimated by investigator. Vaccination related influence factors were estimated by logistic regression. Findings: Overall 3 dose HPV vaccine coverage from Oct. 2017- Mar. 2019 was extremely low: 0.73%, with bivalent vaccine of 0.25%, quadrivalent vaccine of 0.46% and nine-valent vaccine of 0.02%, respectively. 5414 college students participated, and 5307 valid questionnaires were collected. Overall, screening rate of cervical cancer was 11.82% (95%CI: 9.03%, 14.61%) and the coverage of HPV vaccine was pretty low in 3.09% (95%CI: 2.62%,3.56%), with “urban background” (4.62%, 95%CI: 3.82%, 5.42% VS 1.60%, 95%CI: 1.13%, 2.07%), along with increased monthly expense, highest in “≥2000 RMB/ month” group(7.75%, 95%CI: 5.97%, 9.53%), had a higher and significant coverage, and “sexual behavior” group (5.56%, 95%CI: 2.21%, 8.91) was high but not significant. 55.57% of participants were still hesitant and uncertain about vaccination. Uncertain about the long-effect of HPV vaccine was the biggest barrier for they vaccinating (62.75%), followed by high price (54.30%), unheard of HPV vaccines (53.45%), fear of side effects (51.99%) and disbelief in the effectiveness of vaccines (51.84%). Urban background (OR=2.131.36-3.33) ,higher monthly consumption (OR=2.59, 1.85-3.62), aware of vaccination adaptive population (OR=3.06, 1.88-4.99) and HPV infection high risk factors (OR=2.49, 1.08-5.74),and have a clear attitude towards vaccine protection effect, no matter yes (OR=11.88, 4.13-34.18) or no (OR=2.87, 1.30-6.30), were significantly influence factors for their vaccination. Interpretation: Low vaccination rate and vaccination hesitation are important obstacles in China to achieve cervical cancer elimination goals called from WHO. The reasons behind this are the lack of national policies and funding guarantees in the early stage after marketing, the insufficient experience for in-depth education interventions, and insufficient personal awareness. The introduction of HPV vaccines in mainland China is just the beginning, not the end. In the future, the Chinese government still has a long way to go to improve the vaccination rate of target people and strengthen the primary and secondary prevention measures in cervical cancer control and elimination.Funding Statement: The Project for Key Medicine Discipline Construction of Guangzhou Municipality (2013-2015-07).Declaration of Interests: All authors have nothing to disclose.Ethics Approval Statement: This Survey was approved by ethics commute of Guangzhou Center for Disease Control and Prevention. All participants provided informed consent before the questionnaire survey

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yunqingbai完成签到 ,获得积分10
1秒前
南风完成签到,获得积分10
1秒前
sunflower完成签到,获得积分0
1秒前
心灵美亦寒完成签到,获得积分10
2秒前
冲冲冲完成签到,获得积分10
2秒前
tang完成签到,获得积分10
3秒前
4秒前
8秒前
火猫三张大王完成签到,获得积分10
8秒前
小硕土川完成签到,获得积分10
8秒前
是阿龙呀完成签到 ,获得积分10
9秒前
TmmYLU2025完成签到,获得积分10
9秒前
不回首完成签到 ,获得积分10
9秒前
奋斗甜瓜完成签到,获得积分10
9秒前
半岛铁盒发布了新的文献求助10
10秒前
12秒前
plant完成签到,获得积分0
13秒前
uery完成签到,获得积分10
13秒前
眼睛大涵易完成签到,获得积分10
16秒前
秀丽天德完成签到,获得积分10
16秒前
17秒前
大白包子李完成签到,获得积分10
18秒前
18秒前
K先生发布了新的文献求助10
20秒前
俏皮凝梦完成签到,获得积分10
21秒前
百注册发布了新的文献求助10
21秒前
shee完成签到,获得积分20
23秒前
23秒前
曲聋五完成签到 ,获得积分0
23秒前
Polaris发布了新的文献求助10
23秒前
蒙眼过河发布了新的文献求助10
25秒前
竹舍翁暮雨君完成签到 ,获得积分10
26秒前
26秒前
樱木花道的樱完成签到,获得积分10
27秒前
27秒前
香蕉觅云应助saki采纳,获得10
27秒前
大狒狒发布了新的文献求助10
29秒前
半岛铁盒完成签到,获得积分10
29秒前
欣喜成仁完成签到,获得积分10
32秒前
XXXX完成签到 ,获得积分10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
What is the Future of Psychotherapy in Digital Age? Technology, AI Bots, and Psychotherapy after Covid 444
Management and the Arts 310
Teaching Social and Emotional Learning in Physical Education 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7634532
求助须知:如何正确求助?哪些是违规求助? 9208628
关于积分的说明 19748939
捐赠科研通 7202630
什么是DOI,文献DOI怎么找? 3275070
关于科研通互助平台的介绍 2436953
邀请新用户注册赠送积分活动 2271966